Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway

Multidrug resistance (MDR) is one of the major obstacles to the efficiency of cancer chemotherapy, which often results from the overexpression of drug efflux transporters such as P-glycoprotein (P-gp). In the present study, we determined the effect of dasatinib which was approved for imatinib resist...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer Biol Ther
Prif Awduron: Chen, Ting, Wang, Changyuan, Liu, Qi, Meng, Qiang, Sun, Huijun, Huo, Xiaokui, Sun, Pengyuan, Peng, Jinyong, Liu, Zhihao, Yang, Xiaobo, Liu, Kexin
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Taylor & Francis 2014
Pynciau:
Research Papers
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4622436/
https://ncbi.nlm.nih.gov/pubmed/25482933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/15384047.2014.987062
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg